In Vivo Quantification of Endosomal Escape Paves New Roads for RNA Therapeutics
The delivery of nucleic acids via lipid nanoparticles (LNPs) has revolutionized the field of gene therapy and vaccinations, yet a formidable hurdle persists: the efficient escape of these nanoparticles from endosomes into the cytosol. Without this critical step, therapeutic nucleic acids remain trapped in intracellular compartments, drastically reducing their functional efficacy. Addressing this challenge head-on, a recent landmark study introduces a groundbreaking approach that not only enhances the biochemical performance of LNPs but, for the first time, accurately quantifies endosomal escape in a living organism.
The team, led by Jozić et al., engineered a novel library of branched ionizable phospholipids designed to amplify messenger RNA (mRNA) delivery to hepatocytes within the liver. These tailored lipids leverage ionizable character to enhance membrane interaction, allowing for more robust disruption of endosomal membranes and subsequent cargo release. Among this diverse collection, one standout candidate, termed BiP-20, demonstrated exceptional potency, surpassing the current clinical standard, LP01, by an eightfold margin in mediating CRISPR–Cas9 editing of the transthyretin (TTR) gene at subtherapeutic doses.
The rapid pharmacokinetics of BiP-20-enabled LNPs are noteworthy, facilitating swift intracellular trafficking and cargo release, an attribute crucial for minimizing off-target effects and immune activation. However, quantifying these dynamic intracellular processes, notably endosomal escape, remained elusive — until now. Leveraging the genetically engineered LysoTag mouse model, which permits the immunoisolation of liver lysosomes and endosomes, the researchers employed an innovative Lysosomal Barcoding technique. This sophisticated approach enabled the real-time capture and quantification of the fraction of LNPs escaping the endolysosomal pathway.
Remarkably, the findings revealed that approximately 8% of BiP-20 LNP payloads successfully transition from lysosomal compartments into the cytosol within 30 minutes post-administration. This degree of efficiency represents a significant improvement over previous delivery platforms and underscores the precision of the branched ionizable lipid design. Such quantification is a crucial step towards understanding the intracellular bottlenecks of RNA delivery, providing an empirical basis for iterative LNP optimization.
Beyond quantification, the study delved deeply into the molecular underpinnings of endosomal escape by performing comprehensive lysosomal proteomics. This analysis illuminated how BiP-20 uniquely reconfigures protein networks associated with endosomal maturation and recycling. Contrary to classical views favoring late endosome escape, the data implicated manipulation of endolysosomal trafficking pathways as integral to enhanced cargo release.
A pivotal discovery emerged around Rab7, a GTPase enzyme instrumental in late endosomal maturation. The study’s genetic knockdown experiments revealed that loss of Rab7 markedly increased LNP escape efficiency, unveiling a novel avenue for augmenting delivery outcomes. This insight reframes the traditional understanding of intracellular trafficking determinants, suggesting that selective modulation of endosomal maturation states can unlock the full therapeutic potential of LNPs.
The implications of these findings extend well beyond academic interest. Efficient hepatic delivery of gene-editing components, such as CRISPR–Cas9, promises transformative interventions for genetic liver diseases, including transthyretin amyloidosis. The low-dose efficacy of BiP-20 LNPs hints at improved safety profiles and reduced manufacturing burdens, essential for widespread clinical applicability.
Moreover, the generalized methodology for in vivo endosomal escape quantification unlocks unprecedented possibilities in the design and preclinical evaluation of a new generation of nucleic acid therapies. Drug developers can apply these tools to dissect intracellular trafficking with exquisite temporal resolution and organ specificity, accelerating the pipeline from bench to bedside.
In the broader landscape of RNA therapeutics, where mRNA vaccines and gene editing are rapidly ascending, understanding and overcoming intracellular delivery barriers remains the critical bottleneck. The approach pioneered here integrates molecular design, genetic models, and proteomic analysis into a cohesive framework that can be adapted to diverse payloads and target tissues.
Critically, the strategic branching of ionizable phospholipids, as exemplified by BiP-20, enhances the delicate balance between stability in circulation and membrane-disruptive capacity within endosomes. This balance ensures nucleic acid protection en route to target cells while enabling rapid and efficient cytosolic release post internalization.
The measured pharmacokinetics of BiP-20 LNPs, with their rapid onset of escape and editing activity, highlight an improved safety and efficacy window compared to conventional formulations. This rapid action helps mitigate immune recognition and degradation pathways that often limit current LNP-based therapies.
Further, the lysosomal barcoding technology opens doors for detailed kinetic studies of endosomal escape in vivo, a realm previously limited to in vitro proxy assays that often poorly translate to physiological contexts. This leap allows researchers to observe delivery dynamics within the complex liver microenvironment, accounting for cellular heterogeneity and systemic influences.
The study’s multipronged approach—synthetic lipid design, advanced animal models, proteomic profiling, and functional gene editing assays—exemplifies the interdisciplinary innovation required to tackle such a multifaceted biological problem. The collaboration between chemical biologists, geneticists, and bioengineers underscores the evolving nature of therapeutic development.
Looking forward, this work sets a new standard for evaluating and improving LNP delivery platforms. By quantifying endosomal escape with precision and revealing molecular regulators like Rab7, future investigations can rationally design LNPs with tailored trafficking properties, potentially extending therapeutic reach to previously inaccessible organs and cell types.
Ultimately, the findings have broad implications for the burgeoning field of nucleic acid medicines. Unlocking efficient in vivo endosomal escape not only bolsters RNA-based gene editing but also enhances mRNA vaccine efficacy and the delivery of siRNAs, antisense oligonucleotides, and beyond. As the pharmaceutical landscape embraces these modalities, innovations like BiP-20 and the LysoTag-based assay will be instrumental in transforming the promise of RNA therapeutics into pervasive clinical realities.
The new frontier unveiled by Jozić and colleagues thus represents a seminal advance in biomedical delivery science, bringing researchers a step closer to overcoming one of the last frontier challenges in intracellular therapeutics. With the ability to observe, measure, and manipulate endosomal escape in living organisms, the era of truly precision-engineered RNA medicines has arrived.
Subject of Research:
Ionizable lipid nanoparticles and their mechanisms of endosomal escape in liver-targeted RNA delivery.
Article Title:
In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery.
Article References:
Jozić, A., Le Roux, C., Kim, J. et al. In vivo endosomal escape assay identifies mechanisms for efficient hepatic LNP delivery. Nat Biotechnol (2026). https://doi.org/10.1038/s41587-026-03022-6
Image Credits:
AI Generated
DOI:
https://doi.org/10.1038/s41587-026-03022-6
Keywords:
Lipid nanoparticles, Ionizable phospholipids, Endosomal escape, mRNA delivery, CRISPR–Cas9, Lysosomal Barcoding, LysoTag mice, Hepatic gene editing, Rab7, Endosomal maturation, Lysosomal proteomics, RNA therapeutics, Pharmacokinetics, Intracellular trafficking
Tags: branched ionizable phospholipidsCRISPR–Cas9 gene editing efficiencyendosomal escape quantificationenhanced membrane interaction lipidsimproved nucleic acid therapeutic efficacyin vivo liver lipid nanoparticle deliverymRNA delivery to hepatocytesnovel lipid nanoparticle formulationsrapid intracellular trafficking nanoparticlesRNA therapeutics deliverysubtherapeutic dose gene editingtransthyretin gene targeting
